What is the estimated Glomerular Filtration Rate (eGFR) requirement for stage 3 Acute Kidney Injury (AKI) according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

eGFR Requirement for Stage 3 AKI in KDIGO Criteria

According to the KDIGO criteria, Stage 3 AKI includes a decrease in eGFR to less than 35 mL/min/1.73 m² in patients under 18 years of age. 1

KDIGO Definition of Stage 3 AKI

Stage 3 AKI is defined by any of the following criteria:

  • Increase in serum creatinine (SCr) to ≥3.0 times baseline 1
  • Increase in SCr to ≥4.0 mg/dL (353.6 μmol/L) 1
  • Initiation of renal replacement therapy 1
  • In patients <18 years, decrease in eGFR to <35 mL/min/1.73 m² 1
  • Urine output <0.3 mL/kg/h for ≥24 hours 1
  • Anuria for ≥12 hours 1

Important Considerations for AKI Classification

  • The eGFR criterion of <35 mL/min/1.73 m² applies specifically to pediatric patients (under 18 years) 1
  • For adult patients, the KDIGO criteria rely on changes in serum creatinine, urine output, or initiation of renal replacement therapy rather than absolute eGFR values 1
  • The KDIGO definition combines elements from previous RIFLE and AKIN definitions but includes some modifications that have not been fully validated 1

Clinical Implications and Caveats

  • eGFR equations are not accurate during AKI and should not be used to assess kidney function in this setting 2
  • Small fluctuations in serum creatinine (such as an increase from 4.0 to 4.3 mg/dL) may be within normal daily variation in patients with pre-existing CKD 1
  • The KDIGO AKI definition requires an acute increase in serum creatinine by 0.3 mg/dL within 48 hours for patients with SCr ≥4.0 mg/dL to be classified as stage 3 AKI 1
  • This differs from prior AKIN and RIFLE definitions, which required an SCr ≥4.0 mg/dL and increase of 0.5 mg/dL over an unspecified period 1

Long-term Outcomes and Monitoring

  • Patients who experience AKI should be evaluated 3 months after the event for resolution, new onset, or worsening of pre-existing CKD 1
  • AKI events can cause a progressive decline in kidney function, with each subsequent AKI event potentially accelerating this decline 3
  • The risk of developing chronic kidney disease is significantly higher in patients who have experienced AKI 4, 5

Special Populations

  • In pediatric patients, the eGFR criterion (<35 mL/min/1.73 m²) is an important component of the KDIGO staging system 1
  • Different criteria may yield different AKI incidence rates, as demonstrated in studies comparing KDIGO with other definitions 6
  • Patients with baseline CKD require careful interpretation of AKI criteria, as small changes in serum creatinine may have different clinical significance compared to those with normal baseline kidney function 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Obstructive Acute Kidney Injury

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Intermediate and Long-term Outcomes of Survivors of Acute Kidney Injury Episodes: A Large Population-Based Cohort Study.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.